Swiss drug major Roche (RHHBY) reported that its group sales for the first-quarter declined 6% to 14.40 billion Swiss francs from 15.32 billion francs last year. At constant exchange rates, quarterly sales increased 2% as strong demand for newer medicines as well as diagnostics products including immunodiagnostics, clinical chemistry tests and advanced staining solutions more than offset the anticipated decline in COVID-19-related sales and the impact of biosimilar/generic erosion.
After the latest quarter, the impact of the drop in COVID-19-related sales is largely over and there will be no further material impact on Group sales.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.